SCHEMBL6038533

SCHEMBL6038533

N#Cc1ccc(S(=O)(=O)Nc2nc3ccccc3nc2OCCN2CCOCC2)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.49
KMT2A Q03164 3/20 0.49
KDM4E B2RXH2 5/20 0.48
GAA P10253 3/20 0.48
LMNA P02545 2/20 0.48
MAPT P10636 1/20 0.48
HTT P42858 1/20 0.48
HSD17B10 Q99714 1/20 0.47
ALDH1A1 P00352 2/20 0.44
GLA P06280 1/20 0.44
TP53 P04637 1/20 0.44
HPGD P15428 1/20 0.44
CA12 O43570 1/20 0.43
CA1 P00915 1/20 0.43
CA2 P00918 1/20 0.43
CA7 P43166 1/20 0.43
CA9 Q16790 1/20 0.43
MKNK1 Q9BUB5 1/20 0.43
HRH2 P25021 1/20 0.43
HRH1 P35367 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6038751 0.91 MEN1 (0.51) MEN1KMT2AKDM4EGAALMNA
SCHEMBL6038726 0.89 KDM4E (0.60) MEN1KMT2AKDM4EGAALMNA
SCHEMBL6038901 0.88 MEN1 (0.54) MEN1KMT2AKDM4EGAALMNA
SCHEMBL6038773 0.88 MEN1 (0.52) MEN1KMT2AKDM4EGAALMNA
SCHEMBL6038897 0.86 MEN1 (0.52) MEN1KMT2AKDM4EGAALMNA
SCHEMBL6039360 0.86 KMT2A (0.55) MEN1KMT2AKDM4EGAALMNA
SCHEMBL6038525 0.81 KDM4E (0.50) MEN1KMT2AKDM4EGAALMNA
SCHEMBL6038567 0.81 KDM4E (0.59) MEN1KMT2AKDM4EGAALMNA
SCHEMBL6039135 0.81 MEN1 (0.54) MEN1KMT2AKDM4EGAALMNA
SCHEMBL6039281 0.80 KDM4E (0.62) MEN1KMT2AKDM4EGAALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060004010-A1 Ccr4 antagonist and medical use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2006-01-05 US disclosed
EP-1541563-A1 CCR4 ANTAGONIST AND MEDICINAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2005-06-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060004010-A1 Ccr4 antagonist and medical use thereof CCR4, CCR1, CCR9 MEN1 2431/4885KMT2A 4190/4885KDM4E 3561/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.